OQROGet OQRO Pro
Insider trade

Atara Biotherapeutics (ATRA)Chief Accounting Officer sold ~$22K

Yanina Grant-huerta, Chief Accounting Officer at Atara Biotherapeutics, sold ~$22K of Atara Biotherapeutics shares.

~$22K
Approx. value · 1,645 sh @ $13.19
34K
Holds after · shares reported
Traded
Nov 17, 2025
Filed
Nov 19, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 6, 2025Company filing · Form 8-K · RestructuringAnnounced job cuts, closures or a restructuring“On October 6, 2025, Atara Biotherapeutics, Inc. (the “Company”) announced a reduction in its workforce that will impact approximately 29% of its current employees, retaining approximately 15 employees essential to executing on the Company’s strategic priorities.”
  2. Nov 12, 2025Company filing · Form 8-K · ResultsReported its results
  3. Nov 17, 2025 · this disclosureInsiderOfficer sold ~$22K of ATRA shares in the open market

What came next

  1. Nov 17, 2025Insider · 2 peopleInsiders: 4 sales (~$41K)
  2. Dec 30, 2025Company filing · Form 8-K · Material agreementSigned an important agreement
  3. Jan 12, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
  4. Jan 12, 2026Insider10% owner sold ~$489K of ATRA shares in the open market
  5. Feb 20, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
  6. Mar 2, 2026Insider · 2 peopleInsiders: 8 sales (~$26K)
  7. Mar 16, 2026Company filing · Form 8-K · ResultsReported its results
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Atara Biotherapeutics

For Atara Biotherapeutics, OQRO holds 2 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ATRA page.

Other recent filings by Yanina Grant-huerta, Chief Accounting Officer

The full history of Yanina Grant-huerta, Chief Accounting Officer is on the profile page.

How this filing works

Other disclosures at Atara Biotherapeutics

Everything OQRO holds on this company is on its ATRA page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data